PTPI
PTPI
Petros Pharmaceuticals, Inc.Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $990.74K ▼ | $-922.72K ▼ | 0% | $-0.03 ▲ | $-214.92K ▲ |
| Q2-2025 | $0 | $1.8M ▲ | $5.43M ▲ | 0% | $-1.29 ▲ | $-1.8M ▼ |
| Q1-2025 | $0 ▼ | $1.46M ▼ | $-2.26M ▲ | 0% ▲ | $-9.37 ▼ | $-1.46M ▲ |
| Q4-2024 | $725.4K ▼ | $9.59M ▲ | $-9.27M ▼ | -1.28K% ▼ | $-0.13 ▲ | $-8.44M ▼ |
| Q3-2024 | $1.58M | $3.63M | $-2.22M | -140.87% | $-1.15 | $-1.29M |
What's going well?
The company managed to cut its losses significantly this quarter. Operating expenses are down, and interest income helped offset some of the loss.
What's concerning?
There is still no revenue at all, so the business isn't generating sales. The big jump in share count means existing shareholders now own a much smaller piece of the company.
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $6.07M ▼ | $6.13M ▼ | $2.77M ▼ | $3.37M ▼ |
| Q2-2025 | $7.32M ▼ | $7.4M ▼ | $2.95M ▼ | $4.45M ▲ |
| Q1-2025 | $8.93M ▲ | $17.61M ▲ | $27.19M ▲ | $-9.58M ▼ |
| Q4-2024 | $3.71M ▼ | $10.64M ▼ | $18.1M ▲ | $-7.47M ▼ |
| Q3-2024 | $3.89M | $20.69M | $17.58M | $3.12M |
What's financially strong about this company?
PTPI has no debt at all and almost all its assets are in cash, making it very liquid. The company can easily pay its bills and has no hidden financial risks.
What are the financial risks or weaknesses?
Cash and equity are both shrinking, and the company has a long history of losses (negative retained earnings). The drop in deferred revenue could signal weaker future sales.
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-922.72K ▼ | $-1.13M ▲ | $0 | $-117.31K ▲ | $-1.25M ▲ | $-1.13M ▲ |
| Q2-2025 | $4.93M ▲ | $-3.01M ▼ | $0 | $-428.23K ▼ | $-3.44M ▼ | $-3.01M ▼ |
| Q1-2025 | $-1.2M ▲ | $-1.66M ▼ | $0 ▲ | $8.71M ▲ | $7.05M ▲ | $-1.66M ▼ |
| Q4-2024 | $-9.27M ▼ | $965.4K ▲ | $-5.45K ▲ | $-1.14M ▲ | $-184.71K ▲ | $959.96K ▲ |
| Q3-2024 | $-2.22M | $-771.25K | $-19.14K | $-2.77M | $-3.57M | $-790.38K |
What's strong about this company's cash flow?
The cash burn rate dropped sharply this quarter, and the company still has $6.07 million in cash. No new debt or dilution means existing shareholders aren't being squeezed—yet.
What are the cash flow concerns?
The company is still losing real cash every quarter, and net income swung from profit to loss. Without a turnaround, cash reserves will eventually run out, forcing new funding or cuts.
Revenue by Products
| Product | Q1-2024 | Q2-2024 | Q3-2024 | Q4-2024 |
|---|---|---|---|---|
 Medical Devices | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
Revenue by Geography
| Region | Q1-2024 | Q2-2024 | Q3-2024 | Q4-2024 |
|---|---|---|---|---|
 International | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 NonUS | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 UNITED STATES | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
5-Year Trend Analysis
A comprehensive look at Petros Pharmaceuticals, Inc.'s financial evolution and strategic trajectory over the past five years.
Key positives include strong gross margins, a focused strategy in men’s health, and a differentiated, technology-enabled approach to converting prescription therapies to OTC status. The pipeline, anchored by the potential STENDRA OTC switch and H100 for Peyronie’s disease, addresses large or underserved markets. R&D investment has been consistent, and recent cost-cutting has modestly improved operating and cash flow trends, suggesting some operational discipline.
Major concerns stem from persistent operating and net losses, steadily declining revenue, and a severely weakened balance sheet with negative equity and tight liquidity. The company appears dependent on external capital to continue operating, and its history of reverse stock splits and share dilution underlines this reliance. Regulatory risk around key programs is high, and any setbacks could quickly become existential challenges given the limited financial buffer and narrow product base.
The forward picture is highly binary. On one hand, successful regulatory approvals for the STENDRA OTC switch, progress with H100, and meaningful licensing of the Rx-to-OTC platform could transform the company’s growth and cash generation profile. On the other hand, continued revenue erosion, additional delays or failures in the pipeline, or difficulty raising capital could force more aggressive restructuring or strategic alternatives. Overall, the story is driven far more by future regulatory and partnering outcomes than by the current financial performance, and the uncertainty around those outcomes is substantial.
About Petros Pharmaceuticals, Inc.
https://www.petrospharma.comPetros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a patented topical formulation candidate for the treatment of acute Peyronie's disease.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $990.74K ▼ | $-922.72K ▼ | 0% | $-0.03 ▲ | $-214.92K ▲ |
| Q2-2025 | $0 | $1.8M ▲ | $5.43M ▲ | 0% | $-1.29 ▲ | $-1.8M ▼ |
| Q1-2025 | $0 ▼ | $1.46M ▼ | $-2.26M ▲ | 0% ▲ | $-9.37 ▼ | $-1.46M ▲ |
| Q4-2024 | $725.4K ▼ | $9.59M ▲ | $-9.27M ▼ | -1.28K% ▼ | $-0.13 ▲ | $-8.44M ▼ |
| Q3-2024 | $1.58M | $3.63M | $-2.22M | -140.87% | $-1.15 | $-1.29M |
What's going well?
The company managed to cut its losses significantly this quarter. Operating expenses are down, and interest income helped offset some of the loss.
What's concerning?
There is still no revenue at all, so the business isn't generating sales. The big jump in share count means existing shareholders now own a much smaller piece of the company.
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $6.07M ▼ | $6.13M ▼ | $2.77M ▼ | $3.37M ▼ |
| Q2-2025 | $7.32M ▼ | $7.4M ▼ | $2.95M ▼ | $4.45M ▲ |
| Q1-2025 | $8.93M ▲ | $17.61M ▲ | $27.19M ▲ | $-9.58M ▼ |
| Q4-2024 | $3.71M ▼ | $10.64M ▼ | $18.1M ▲ | $-7.47M ▼ |
| Q3-2024 | $3.89M | $20.69M | $17.58M | $3.12M |
What's financially strong about this company?
PTPI has no debt at all and almost all its assets are in cash, making it very liquid. The company can easily pay its bills and has no hidden financial risks.
What are the financial risks or weaknesses?
Cash and equity are both shrinking, and the company has a long history of losses (negative retained earnings). The drop in deferred revenue could signal weaker future sales.
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-922.72K ▼ | $-1.13M ▲ | $0 | $-117.31K ▲ | $-1.25M ▲ | $-1.13M ▲ |
| Q2-2025 | $4.93M ▲ | $-3.01M ▼ | $0 | $-428.23K ▼ | $-3.44M ▼ | $-3.01M ▼ |
| Q1-2025 | $-1.2M ▲ | $-1.66M ▼ | $0 ▲ | $8.71M ▲ | $7.05M ▲ | $-1.66M ▼ |
| Q4-2024 | $-9.27M ▼ | $965.4K ▲ | $-5.45K ▲ | $-1.14M ▲ | $-184.71K ▲ | $959.96K ▲ |
| Q3-2024 | $-2.22M | $-771.25K | $-19.14K | $-2.77M | $-3.57M | $-790.38K |
What's strong about this company's cash flow?
The cash burn rate dropped sharply this quarter, and the company still has $6.07 million in cash. No new debt or dilution means existing shareholders aren't being squeezed—yet.
What are the cash flow concerns?
The company is still losing real cash every quarter, and net income swung from profit to loss. Without a turnaround, cash reserves will eventually run out, forcing new funding or cuts.
Revenue by Products
| Product | Q1-2024 | Q2-2024 | Q3-2024 | Q4-2024 |
|---|---|---|---|---|
| Medical Devices | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
Revenue by Geography
| Region | Q1-2024 | Q2-2024 | Q3-2024 | Q4-2024 |
|---|---|---|---|---|
| International | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
| NonUS | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
| UNITED STATES | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
5-Year Trend Analysis
A comprehensive look at Petros Pharmaceuticals, Inc.'s financial evolution and strategic trajectory over the past five years.
Key positives include strong gross margins, a focused strategy in men’s health, and a differentiated, technology-enabled approach to converting prescription therapies to OTC status. The pipeline, anchored by the potential STENDRA OTC switch and H100 for Peyronie’s disease, addresses large or underserved markets. R&D investment has been consistent, and recent cost-cutting has modestly improved operating and cash flow trends, suggesting some operational discipline.
Major concerns stem from persistent operating and net losses, steadily declining revenue, and a severely weakened balance sheet with negative equity and tight liquidity. The company appears dependent on external capital to continue operating, and its history of reverse stock splits and share dilution underlines this reliance. Regulatory risk around key programs is high, and any setbacks could quickly become existential challenges given the limited financial buffer and narrow product base.
The forward picture is highly binary. On one hand, successful regulatory approvals for the STENDRA OTC switch, progress with H100, and meaningful licensing of the Rx-to-OTC platform could transform the company’s growth and cash generation profile. On the other hand, continued revenue erosion, additional delays or failures in the pipeline, or difficulty raising capital could force more aggressive restructuring or strategic alternatives. Overall, the story is driven far more by future regulatory and partnering outcomes than by the current financial performance, and the uncertainty around those outcomes is substantial.
CEO
Fady Boctor
Compensation Summary
(Year 2020)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-05-01 | Reverse | 1:25 |
| 2022-12-01 | Reverse | 1:10 |
Ratings Snapshot
Rating : C